Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?

The mainstay of treatment for metastatic prostate cancer is androgen deprivation therapy (ADT). Outcomes with ADT are variable but control of hormone-sensitive prostate cancer (HSPC) can often be achieved for many years. Death from prostate cancer is usually due to the development of escape variants...

Descripción completa

Detalles Bibliográficos
Autor principal: Davis, Ian D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969504/
https://www.ncbi.nlm.nih.gov/pubmed/35371297
http://dx.doi.org/10.1177/17588359221086827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969504/
https://www.ncbi.nlm.nih.gov/pubmed/35371297
http://dx.doi.org/10.1177/17588359221086827

Ejemplares similares